<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886493</url>
  </required_header>
  <id_info>
    <org_study_id>J18116</org_study_id>
    <secondary_id>IRB00182718</secondary_id>
    <nct_id>NCT03886493</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer</brief_title>
  <official_title>Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, single arm, open-label phase II study evaluating the safety,&#xD;
      anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical&#xD;
      prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single arm, open-label phase II study evaluating the safety,&#xD;
      anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical&#xD;
      prostatectomy in men with high-risk localized prostate cancer (this trial will enroll men&#xD;
      with at least high risk prostate cancer defined by NCCN Guidelines Version 2.2017 = clinical&#xD;
      stage ≥T3a or PSA &gt;20 ng/mL or Gleason score ≥8).&#xD;
&#xD;
      Patients will be recruited from the outpatient Urology clinic. Men will be treated with&#xD;
      dupilumab 600 mg subcutaneously (SQ) on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36,&#xD;
      43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent,&#xD;
      prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue&#xD;
      will be examined for the secondary endpoints.&#xD;
&#xD;
      Follow-up evaluation for adverse events will occur 30 days and 60 days after surgery.&#xD;
      Patients will then be followed by their urologists according to standard institutional&#xD;
      practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6&#xD;
      (±2) months during years 2-3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual due to COVID-19 pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Men will be treated with dupilumab 600 mg s.q. on day 1, and then 300 mg s.q. on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. Fourteen days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints. Follow-up evaluation for adverse events will occur 30 days and 60 days after surgery. Patients will then be followed by their urologists according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in M2-TAM Infiltration From Baseline</measure>
    <time_frame>change from baseline to up to 59 days post-intervention</time_frame>
    <description>Change in M2-TAM infiltration (number of macrophages / cell nuclei per high power field [hpf]) measured in pre- dupilumab biopsy to M2-TAM infiltration measured in post-dupilumab specimen collected at time of radical prostatectomy (up to 59 days post-intervention). Degree of TAM infiltration will be analyzed using immunohistochemical staining for CD206. It is hypothesized that a positive value will be associated with better outcome and a negative value will reflect a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as Assessed by Number of Participants Experiencing Adverse Events</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
    <description>Adverse events defined by NCI Common Toxicity Criteria version 4.0 (NCI CTCAE v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Assessed by Number of Participants Who Have an Average Blood Loss in Excess of 2500 mL During Prostatectomy</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Assessed by Number of Participants With Average Prostatectomy Operative Time in Excess of 3.5 Hours</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Assessed by Number of Participants With Average Hospital Stay in Excess of 4 Days Post-prostatectomy</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ T-cell Infiltration in Post-treatment Prostate Glands</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
    <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell and Treg Infiltration in Post-treatment Prostate Glands</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
    <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of Apoptosis Marker (Annexin V) in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage in Tumor Tissue</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
    <description>Mean staining percentage of Annexin V in tumor tissue, using TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of Cell Proliferation in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage of Ki-67 in Tumor Tissue</measure>
    <time_frame>up to 59 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Pathological Complete Response</measure>
    <time_frame>1 month post-prostatectomy</time_frame>
    <description>Pathological response is defined as the absence of tumor identification by study pathologist on standard histological analysis of resected prostate specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieve an Undetectable PSA at 2 Months Post-prostatectomy</measure>
    <time_frame>2 months post-prostatectomy</time_frame>
    <description>Proportion of participants with PSA &lt;0.1ng/mL by 2 months after prostatectomy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dupixent Subcutaneous (SQ) Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
    <arm_group_label>Dupixent Subcutaneous (SQ) Injection</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for this study, patients must meet all of the following criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate (clinical stage T1c-T3b, N0,&#xD;
             M0) without involvement of lymph nodes, bone, or visceral organs&#xD;
&#xD;
          -  Initial prostate biopsy is available for central pathologic review, and is confirmed&#xD;
             to show at least 2 positive cores and a Gleason sum of ≥7&#xD;
&#xD;
          -  Radical prostatectomy has been scheduled at Johns Hopkins Hospital&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1, or Karnofsky score ≥&#xD;
             70%&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function:&#xD;
&#xD;
               -  WBC &gt;3,000 cells/mm3&#xD;
&#xD;
               -  ANC &gt;1,500 cells/mm3&#xD;
&#xD;
               -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               -  Platelet count &gt;100,000 cells/mm3&#xD;
&#xD;
               -  Serum creatinine &lt;3 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum bilirubin &lt;3 × ULN&#xD;
&#xD;
               -  ALT &lt;5 × ULN&#xD;
&#xD;
               -  AST &lt;5 × ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt;5 × ULN&#xD;
&#xD;
          -  Willingness to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information, and the ability to comply with the study&#xD;
             requirements (note: HIPAA authorization will be included in the informed consent)&#xD;
&#xD;
          -  Willingness to use barrier contraception from the time of first dose of DUPILUMAB&#xD;
             until the time of prostatectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To be eligible for this study, patients should not meet any of the following criteria:&#xD;
&#xD;
          -  Presence of known lymph node involvement or distant metastases&#xD;
&#xD;
          -  Other histologic types of prostate cancers such as ductal, sarcomatous, lymphoma,&#xD;
             small cell, and neuroendocrine tumors&#xD;
&#xD;
          -  Prior radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for&#xD;
             prostate cancer&#xD;
&#xD;
          -  Prior immunotherapy/vaccine therapy for prostate cancer&#xD;
&#xD;
          -  Concomitant treatment with other hormonal therapy or 5α-reductase inhibitors&#xD;
&#xD;
          -  Current use of systemic corticosteroids or use of corticosteroids within 4 weeks of&#xD;
             enrollment (inhaled corticosteroids for asthma or COPD are permitted)&#xD;
&#xD;
          -  Use of experimental agents for prostate cancer within the past 3 months from time of&#xD;
             screening&#xD;
&#xD;
          -  History or presence of autoimmune disease requiring systemic immunosuppression&#xD;
             (including but not limited to: inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, vasculitis, rheumatoid arthritis, scleroderma, multiple sclerosis,&#xD;
             hemolytic anemia, Sjögren syndrome, and sarcoidosis)&#xD;
&#xD;
          -  History of malignancy within the last 3 years, with the exception of non-melanoma skin&#xD;
             cancers and superficial bladder cancer&#xD;
&#xD;
          -  Uncontrolled major active infectious, cardiovascular, pulmonary, hematologic, or&#xD;
             psychiatric illnesses that would make the patient a poor study candidate&#xD;
&#xD;
          -  Known prior or current history of HIV and/or hepatitis B/C&#xD;
&#xD;
          -  Significant eye disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Subjects must have a prostate in order to be eligible for this trial.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Pienta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <results_first_submitted>September 17, 2021</results_first_submitted>
  <results_first_submitted_qc>September 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-risk prostate cancer</keyword>
  <keyword>localized prostate cancer</keyword>
  <keyword>prior to prostatectomy</keyword>
  <keyword>neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03886493/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dupixent Subcutaneous (SQ) Injection</title>
          <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dupixent Subcutaneous (SQ) Injection</title>
          <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in M2-TAM Infiltration From Baseline</title>
        <description>Change in M2-TAM infiltration (number of macrophages / cell nuclei per high power field [hpf]) measured in pre- dupilumab biopsy to M2-TAM infiltration measured in post-dupilumab specimen collected at time of radical prostatectomy (up to 59 days post-intervention). Degree of TAM infiltration will be analyzed using immunohistochemical staining for CD206. It is hypothesized that a positive value will be associated with better outcome and a negative value will reflect a worse outcome.</description>
        <time_frame>change from baseline to up to 59 days post-intervention</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in M2-TAM Infiltration From Baseline</title>
          <description>Change in M2-TAM infiltration (number of macrophages / cell nuclei per high power field [hpf]) measured in pre- dupilumab biopsy to M2-TAM infiltration measured in post-dupilumab specimen collected at time of radical prostatectomy (up to 59 days post-intervention). Degree of TAM infiltration will be analyzed using immunohistochemical staining for CD206. It is hypothesized that a positive value will be associated with better outcome and a negative value will reflect a worse outcome.</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety as Assessed by Number of Participants Experiencing Adverse Events</title>
        <description>Adverse events defined by NCI Common Toxicity Criteria version 4.0 (NCI CTCAE v4.0)</description>
        <time_frame>up to 59 days post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Assessed by Number of Participants Experiencing Adverse Events</title>
          <description>Adverse events defined by NCI Common Toxicity Criteria version 4.0 (NCI CTCAE v4.0)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Assessed by Number of Participants Who Have an Average Blood Loss in Excess of 2500 mL During Prostatectomy</title>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Only 6/7 participants had a prostatectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Assessed by Number of Participants Who Have an Average Blood Loss in Excess of 2500 mL During Prostatectomy</title>
          <population>Only 6/7 participants had a prostatectomy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Assessed by Number of Participants With Average Prostatectomy Operative Time in Excess of 3.5 Hours</title>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Only 6/7 participants had a prostatectomy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Assessed by Number of Participants With Average Prostatectomy Operative Time in Excess of 3.5 Hours</title>
          <population>Only 6/7 participants had a prostatectomy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Assessed by Number of Participants With Average Hospital Stay in Excess of 4 Days Post-prostatectomy</title>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Only 6/7 participants had a prostatectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Assessed by Number of Participants With Average Hospital Stay in Excess of 4 Days Post-prostatectomy</title>
          <population>Only 6/7 participants had a prostatectomy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8+ T-cell Infiltration in Post-treatment Prostate Glands</title>
        <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>CD8+ T-cell Infiltration in Post-treatment Prostate Glands</title>
          <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell and Treg Infiltration in Post-treatment Prostate Glands</title>
        <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell and Treg Infiltration in Post-treatment Prostate Glands</title>
          <description>mean CD4+ T-cell staining percentage and CD4+/Treg ratio in harvested tumor tissue collected from prostatectomy specimen</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expression of Apoptosis Marker (Annexin V) in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage in Tumor Tissue</title>
        <description>Mean staining percentage of Annexin V in tumor tissue, using TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) staining.</description>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of Apoptosis Marker (Annexin V) in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage in Tumor Tissue</title>
          <description>Mean staining percentage of Annexin V in tumor tissue, using TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) staining.</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expression of Cell Proliferation in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage of Ki-67 in Tumor Tissue</title>
        <time_frame>up to 59 days post-intervention</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Expression of Cell Proliferation in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage of Ki-67 in Tumor Tissue</title>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Pathological Complete Response</title>
        <description>Pathological response is defined as the absence of tumor identification by study pathologist on standard histological analysis of resected prostate specimens.</description>
        <time_frame>1 month post-prostatectomy</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Pathological Complete Response</title>
          <description>Pathological response is defined as the absence of tumor identification by study pathologist on standard histological analysis of resected prostate specimens.</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Achieve an Undetectable PSA at 2 Months Post-prostatectomy</title>
        <description>Proportion of participants with PSA &lt;0.1ng/mL by 2 months after prostatectomy</description>
        <time_frame>2 months post-prostatectomy</time_frame>
        <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
        <group_list>
          <group group_id="O1">
            <title>Dupixent Subcutaneous (SQ) Injection</title>
            <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Achieve an Undetectable PSA at 2 Months Post-prostatectomy</title>
          <description>Proportion of participants with PSA &lt;0.1ng/mL by 2 months after prostatectomy</description>
          <population>Data could not be collected for this outcome measure due to COVID-19 pandemic restrictions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dupixent Subcutaneous (SQ) Injection</title>
          <description>Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.&#xD;
Dupilumab: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>edema in right calf and ankle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>elevated hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, intermittent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Increased creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>reproductive system disorder, other blood in ejaculate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>laryngeal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>induration at injection site on abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>maculo papular rash on abdomen</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pruritis at site of injection on abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Right AC bruising related to blood draw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin ulceration upper lip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Pienta, M.D.</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-502-3137</phone>
      <email>kpienta1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

